Financials in USD. Standardized financial statements.
A compact view of how Armata Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $4.90M | $5.17M | $4.53M | $5.51M | $4.47M | $823,000 | $0 | $0 | $115,000 | $260,000 |
| Revenue Growth? | -5.2% | +14.2% | -17.8% | +23.1% | +443.6% | 0.0% | 0.0% | -100.0% | -55.8% | 0.0% |
| Cost of Revenue? | $1.53M | $34.43M | $972,000 | $35.02M | $20.02M | $14.44M | $1.35M | $1.35M | $374,000 | $369,000 |
| Gross Profit? | $3.37M | -$29.25M | $3.56M | -$29.51M | -$15.54M | -$13.62M | -$1.35M | -$1.35M | -$259,000 | -$109,000 |
| Gross Margin? | +68.8% | -565.4% | +78.5% | -535.7% | -347.4% | -1655.0% | 0.0% | 0.0% | -225.2% | -41.9% |
| Operating Expenses? | $34.59M | $13.18M | $44.45M | $7.44M | $8.28M | $7.97M | $17.74M | $9.54M | $16.27M | $23.64M |
| Operating Income? | -$31.22M | -$42.44M | -$40.89M | -$36.95M | -$23.82M | -$21.59M | -$19.09M | -$12.52M | -$16.16M | -$23.38M |
| EBITDA? | -$29.69M | -$41.11M | -$65.45M | -$36.05M | -$21.92M | -$20.44M | -$17.20M | -$9.54M | -$9.98M | -$13.46M |
| Income Before Tax | -$173.80M | -$18.92M | -$69.05M | -$36.92M | -$23.16M | -$22.18M | -$19.48M | -$16.70M | -$14.14M | -$19.39M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$328,000 | -$1.30M | -$556,000 |
| Net Income? | -$173.80M | -$18.92M | -$69.05M | -$36.92M | -$23.16M | -$22.18M | -$19.48M | -$12.11M | -$12.84M | -$18.84M |
| EPS? | $-4.80 | $-0.52 | $-1.91 | $-1.08 | $-0.96 | $-1.35 | $-2.43 | $-8.90 | $-28.14 | $-345.80 |
| Diluted EPS? | $-4.80 | $-0.52 | $-1.91 | $-1.08 | $-0.96 | $-1.35 | $-2.43 | $-8.90 | $-27.34 | $-345.80 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality